Ricin a chain conjugated with monoclonal antibodies selectively killing human carcinoma cells in vitro

Silvana Canevari, Rosaria Orlandi, Marina Ripamonti, Elda Tagliabue, Salvatore Aguanno, Silvia Miotti, Sylvie Menard, Maria Ines Colnaghi

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Ricin A chain was coupled to murine monoclonal antibodies MBr1 and MOv2 respectively raised against human breast and ovarian carcinomas. Inhibition of protein synthesis only occurred in those cultured human tumor cells bearing the appropriate target antigens, demonstrating that both components of the conjugate were unchanged in regards to specificity and toxicity. Conjugates were 125-200 times more efficient in inhibiting [3H]proline incorporation than the uncoupled ricin A chain. They were however unable to kill the entire population of the appropriate cells even after repeated treatment. Although the two monoclonal antibodies had similar binding kinetics, the conjugates differed in their cytotoxicity kinetics. The MBr1-ricin A chain conjugate had slow kinetics, and about 20 hours were needed to obtain a protein synthesis inhibition above 50% on the appropriate line (mammary carcinoma MCF-7). In contrast, the MOv2-ricin A chain conjugate showed very fast kinetics, reaching 50% inhibition after only 30 minutes of treatment on both appropriate cell lines SW626 and HT-29 from ovarian and colon carcinomas, respectively. Growth conditions of cell lines, i.e., adherent cells versus suspended cells, and plating time were found to greatly influence the conjugates killing efficiencies. These studies confirm the possibility of preparing ricin A chain-antibody conjugates, which retain specific cytotoxicity against tumor cells; but they also underline the need for further in vitro studies of various parameters before one considers a therapeutic use of such conjugates.

Original languageEnglish
Pages (from-to)831-839
Number of pages9
JournalJournal of the National Cancer Institute
Volume75
Issue number5
DOIs
Publication statusPublished - Nov 1 1985

Fingerprint

Ricin
Monoclonal Antibodies
Carcinoma
Breast Neoplasms
Cultured Tumor Cells
Cell Line
Therapeutic Uses
Proline
Colon
Proteins
In Vitro Techniques
Antigens
Antibodies
Growth
Population
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ricin a chain conjugated with monoclonal antibodies selectively killing human carcinoma cells in vitro. / Canevari, Silvana; Orlandi, Rosaria; Ripamonti, Marina; Tagliabue, Elda; Aguanno, Salvatore; Miotti, Silvia; Menard, Sylvie; Colnaghi, Maria Ines.

In: Journal of the National Cancer Institute, Vol. 75, No. 5, 01.11.1985, p. 831-839.

Research output: Contribution to journalArticle

Canevari, Silvana ; Orlandi, Rosaria ; Ripamonti, Marina ; Tagliabue, Elda ; Aguanno, Salvatore ; Miotti, Silvia ; Menard, Sylvie ; Colnaghi, Maria Ines. / Ricin a chain conjugated with monoclonal antibodies selectively killing human carcinoma cells in vitro. In: Journal of the National Cancer Institute. 1985 ; Vol. 75, No. 5. pp. 831-839.
@article{3b9933a6a684491184b5ae6b7f30d6af,
title = "Ricin a chain conjugated with monoclonal antibodies selectively killing human carcinoma cells in vitro",
abstract = "Ricin A chain was coupled to murine monoclonal antibodies MBr1 and MOv2 respectively raised against human breast and ovarian carcinomas. Inhibition of protein synthesis only occurred in those cultured human tumor cells bearing the appropriate target antigens, demonstrating that both components of the conjugate were unchanged in regards to specificity and toxicity. Conjugates were 125-200 times more efficient in inhibiting [3H]proline incorporation than the uncoupled ricin A chain. They were however unable to kill the entire population of the appropriate cells even after repeated treatment. Although the two monoclonal antibodies had similar binding kinetics, the conjugates differed in their cytotoxicity kinetics. The MBr1-ricin A chain conjugate had slow kinetics, and about 20 hours were needed to obtain a protein synthesis inhibition above 50{\%} on the appropriate line (mammary carcinoma MCF-7). In contrast, the MOv2-ricin A chain conjugate showed very fast kinetics, reaching 50{\%} inhibition after only 30 minutes of treatment on both appropriate cell lines SW626 and HT-29 from ovarian and colon carcinomas, respectively. Growth conditions of cell lines, i.e., adherent cells versus suspended cells, and plating time were found to greatly influence the conjugates killing efficiencies. These studies confirm the possibility of preparing ricin A chain-antibody conjugates, which retain specific cytotoxicity against tumor cells; but they also underline the need for further in vitro studies of various parameters before one considers a therapeutic use of such conjugates.",
author = "Silvana Canevari and Rosaria Orlandi and Marina Ripamonti and Elda Tagliabue and Salvatore Aguanno and Silvia Miotti and Sylvie Menard and Colnaghi, {Maria Ines}",
year = "1985",
month = "11",
day = "1",
doi = "10.1093/jnci/75.5.831",
language = "English",
volume = "75",
pages = "831--839",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Ricin a chain conjugated with monoclonal antibodies selectively killing human carcinoma cells in vitro

AU - Canevari, Silvana

AU - Orlandi, Rosaria

AU - Ripamonti, Marina

AU - Tagliabue, Elda

AU - Aguanno, Salvatore

AU - Miotti, Silvia

AU - Menard, Sylvie

AU - Colnaghi, Maria Ines

PY - 1985/11/1

Y1 - 1985/11/1

N2 - Ricin A chain was coupled to murine monoclonal antibodies MBr1 and MOv2 respectively raised against human breast and ovarian carcinomas. Inhibition of protein synthesis only occurred in those cultured human tumor cells bearing the appropriate target antigens, demonstrating that both components of the conjugate were unchanged in regards to specificity and toxicity. Conjugates were 125-200 times more efficient in inhibiting [3H]proline incorporation than the uncoupled ricin A chain. They were however unable to kill the entire population of the appropriate cells even after repeated treatment. Although the two monoclonal antibodies had similar binding kinetics, the conjugates differed in their cytotoxicity kinetics. The MBr1-ricin A chain conjugate had slow kinetics, and about 20 hours were needed to obtain a protein synthesis inhibition above 50% on the appropriate line (mammary carcinoma MCF-7). In contrast, the MOv2-ricin A chain conjugate showed very fast kinetics, reaching 50% inhibition after only 30 minutes of treatment on both appropriate cell lines SW626 and HT-29 from ovarian and colon carcinomas, respectively. Growth conditions of cell lines, i.e., adherent cells versus suspended cells, and plating time were found to greatly influence the conjugates killing efficiencies. These studies confirm the possibility of preparing ricin A chain-antibody conjugates, which retain specific cytotoxicity against tumor cells; but they also underline the need for further in vitro studies of various parameters before one considers a therapeutic use of such conjugates.

AB - Ricin A chain was coupled to murine monoclonal antibodies MBr1 and MOv2 respectively raised against human breast and ovarian carcinomas. Inhibition of protein synthesis only occurred in those cultured human tumor cells bearing the appropriate target antigens, demonstrating that both components of the conjugate were unchanged in regards to specificity and toxicity. Conjugates were 125-200 times more efficient in inhibiting [3H]proline incorporation than the uncoupled ricin A chain. They were however unable to kill the entire population of the appropriate cells even after repeated treatment. Although the two monoclonal antibodies had similar binding kinetics, the conjugates differed in their cytotoxicity kinetics. The MBr1-ricin A chain conjugate had slow kinetics, and about 20 hours were needed to obtain a protein synthesis inhibition above 50% on the appropriate line (mammary carcinoma MCF-7). In contrast, the MOv2-ricin A chain conjugate showed very fast kinetics, reaching 50% inhibition after only 30 minutes of treatment on both appropriate cell lines SW626 and HT-29 from ovarian and colon carcinomas, respectively. Growth conditions of cell lines, i.e., adherent cells versus suspended cells, and plating time were found to greatly influence the conjugates killing efficiencies. These studies confirm the possibility of preparing ricin A chain-antibody conjugates, which retain specific cytotoxicity against tumor cells; but they also underline the need for further in vitro studies of various parameters before one considers a therapeutic use of such conjugates.

UR - http://www.scopus.com/inward/record.url?scp=0022344482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022344482&partnerID=8YFLogxK

U2 - 10.1093/jnci/75.5.831

DO - 10.1093/jnci/75.5.831

M3 - Article

VL - 75

SP - 831

EP - 839

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 5

ER -